Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method.

<h4>Background</h4>Diabetes costs represent a large burden to both patients and the health care system. However, few studies that examine the economic consequences of diabetes have distinguished between the two major forms, type 1 and type 2 diabetes, despite differences in underlying pa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Betty Tao, Massimo Pietropaolo, Mark Atkinson, Desmond Schatz, David Taylor
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2010
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/57aec89f168b48408ed6aeadd088181d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:57aec89f168b48408ed6aeadd088181d
record_format	dspace
spelling	oai:doaj.org-article:57aec89f168b48408ed6aeadd088181d2021-12-02T20:20:11ZEstimating the cost of type 1 diabetes in the U.S.: a propensity score matching method.1932-620310.1371/journal.pone.0011501https://doaj.org/article/57aec89f168b48408ed6aeadd088181d2010-07-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20634976/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Diabetes costs represent a large burden to both patients and the health care system. However, few studies that examine the economic consequences of diabetes have distinguished between the two major forms, type 1 and type 2 diabetes, despite differences in underlying pathologies. Combining the two diseases implies that there is no difference between the costs of type 1 and type 2 diabetes to a patient. In this study, we examine the costs of type 1 diabetes, which is often overlooked due to the larger population of type 2 patients, and compare them to the estimated costs of diabetes reported in the literature.<h4>Methodology/principal findings</h4>Using a nationally representative dataset, we estimate yearly and lifetime medical and indirect costs of type 1 diabetes by implementing a matching method to compare a patient with type 1 diabetes to a similar individual without the disease. We find that each year type 1 diabetes costs this country $14.4 billion (11.5-17.3) in medical costs and lost income. In terms of lost income, type 1 patients incur a disproportionate share of type 1 and type 2 costs. Further, if the disease were eliminated by therapeutic intervention, an estimated $10.6 billion (7.2-14.0) incurred by a new cohort and $422.9 billion (327.2-519.4) incurred by the existing number of type 1 diabetic patients over their lifetime would be avoided.<h4>Conclusions/significance</h4>We find that the costs attributed to type 1 diabetes are disproportionately higher than the number of type 1 patients compared with type 2 patients, suggesting that combining the two diseases when estimating costs is not appropriate. This study and another recent contribution provides a necessary first step in estimating the substantial costs of type 1 diabetes on the U.S.Betty TaoMassimo PietropaoloMark AtkinsonDesmond SchatzDavid TaylorPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 5, Iss 7, p e11501 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Betty Tao Massimo Pietropaolo Mark Atkinson Desmond Schatz David Taylor Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method.
description	<h4>Background</h4>Diabetes costs represent a large burden to both patients and the health care system. However, few studies that examine the economic consequences of diabetes have distinguished between the two major forms, type 1 and type 2 diabetes, despite differences in underlying pathologies. Combining the two diseases implies that there is no difference between the costs of type 1 and type 2 diabetes to a patient. In this study, we examine the costs of type 1 diabetes, which is often overlooked due to the larger population of type 2 patients, and compare them to the estimated costs of diabetes reported in the literature.<h4>Methodology/principal findings</h4>Using a nationally representative dataset, we estimate yearly and lifetime medical and indirect costs of type 1 diabetes by implementing a matching method to compare a patient with type 1 diabetes to a similar individual without the disease. We find that each year type 1 diabetes costs this country $14.4 billion (11.5-17.3) in medical costs and lost income. In terms of lost income, type 1 patients incur a disproportionate share of type 1 and type 2 costs. Further, if the disease were eliminated by therapeutic intervention, an estimated $10.6 billion (7.2-14.0) incurred by a new cohort and $422.9 billion (327.2-519.4) incurred by the existing number of type 1 diabetic patients over their lifetime would be avoided.<h4>Conclusions/significance</h4>We find that the costs attributed to type 1 diabetes are disproportionately higher than the number of type 1 patients compared with type 2 patients, suggesting that combining the two diseases when estimating costs is not appropriate. This study and another recent contribution provides a necessary first step in estimating the substantial costs of type 1 diabetes on the U.S.
format	article
author	Betty Tao Massimo Pietropaolo Mark Atkinson Desmond Schatz David Taylor
author_facet	Betty Tao Massimo Pietropaolo Mark Atkinson Desmond Schatz David Taylor
author_sort	Betty Tao
title	Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method.
title_short	Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method.
title_full	Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method.
title_fullStr	Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method.
title_full_unstemmed	Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method.
title_sort	estimating the cost of type 1 diabetes in the u.s.: a propensity score matching method.
publisher	Public Library of Science (PLoS)
publishDate	2010
url	https://doaj.org/article/57aec89f168b48408ed6aeadd088181d
work_keys_str_mv	AT bettytao estimatingthecostoftype1diabetesintheusapropensityscorematchingmethod AT massimopietropaolo estimatingthecostoftype1diabetesintheusapropensityscorematchingmethod AT markatkinson estimatingthecostoftype1diabetesintheusapropensityscorematchingmethod AT desmondschatz estimatingthecostoftype1diabetesintheusapropensityscorematchingmethod AT davidtaylor estimatingthecostoftype1diabetesintheusapropensityscorematchingmethod
_version_	1718374165610758144

Estimating the cost of type 1 diabetes in the U.S.: a propensity score matching method.

Ejemplares similares